Princeton, NJ -- (SBWIRE) -- 06/22/2018 -- The global preimplantation genetic testing market is expected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%. The growth of this market is majorly driven by the rising rate of infertility across the globe, increasing number of fertility clinics worldwide, public-private investments in the field of preimplantation genetic testing, technological advancements in the field of genetic analysis, and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.

Explore More Information about report @ https://www.researchcosmos.com/reports/global-preimplantation-genetic-testing-market-analysis-and-forecast-to-2022-growth-opportunity-ass/6005746

The report analyzes the global preimplantation genetic testing market by technology, product & service, procedure type, application, end user, and region. Based on technology, the next-generation sequencing (NGS) segment accounted for the largest share owing to the advantages offered by NGS such as reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes, and reduction in human errors due to increased automation.

By product & service, the reagents & consumables segment accounted for the largest market share owing to expanding application horizons of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders). Based on procedure type, the genetic screening segment accounted for the largest share due to continuous decline in female fertility (due to rising maternal age) and benefits offered by PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

Request free sample @ https://www.researchcosmos.com/request/6005746

In terms of application, the aneuploidy segment held the largest share in 2016. Factors such as increasing maternal age and rising incidence of aneuploidy have led to the growth of this segment. Among end users, the maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market due to factors such as increasing number of fertility centers and the high treatment success rate at such centers.

This report covers the preimplantation genetic testing market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global preimplantation genetic testing market in 2016, followed by Europe. The large share in the North American region is mainly attributed to the rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, and the ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS). The Asia-Pacific region is expected to register the highest growth rate during the forecast period, due to the growing focus of players on emerging markets and improvements in healthcare infrastructure in these regions.

The high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the key factors restraining the growth of this market.

Illumina, Inc. (U.S.) dominates the market through its wide range of technologically advanced and innovative preimplantation genetic testing products. The company adopts the strategy of agreements and partnerships to maintain its leadership position in the market.

Check for discount @ https://www.researchcosmos.com/discount/6005746

Other prominent players in the preimplantation genetic testing market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

About Research Cosmos
Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We're associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.

Contact Us:
Kevin Stewart
Sales Manager
Research Cosmos
www.researchcosmos.com
kevin@researchcosmos.com
# +1 888 709 8757